We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Spells Out ‘Refusal to File’ Scenarios for NDAs and BLAs
FDA Spells Out ‘Refusal to File’ Scenarios for NDAs and BLAs
The FDA issued draft guidance on when CDER may refuse to file new drug applications and biologics license applications, outlining errors or omissions that can lead them to classify the application as incomplete.